A systematic review and a meta-analysis concluded that IDH1 mutations confer worse OS and event-free survival (EFS), especially in patients with normal cytogenetics, and that IDH2 mutation improves OS particularly in patients with intermediate-risk AML [47]. The gene discussed is IDH1; the disease is acute myeloid leukemia.